ITI-007: Completed Phase III enrollment

Intra-Cellular completed enrollment of 696 patients having an acute exacerbation of psychosis in the double-blind, U.S. Phase III ITI-007-302 trial comparing 20 and 60 mg oral ITI-007 once daily for 6...